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Cell-Specific Dystrophin/Dystroglycan Com-
plexes
A schematic cartoon adapted from Sherman
et al., 2001 (this issue of Neuron) compares
the dystrophin/dystroglycan/laminin axis in
skeletal muscle and Schwann cells.
ward they must maintain themselves not as a flat sheet, nal cytoplasm, and myelin-forming Schwann cells to the
outer surface adjacent to the basal lamina (Scherer etbut as cylinders surrounding tightly compact rolls of
membrane. This new activity and geometry suggest the al., 1995, and references in Sherman et al., 2001). The
latter localization suggested periaxin as a good candi-need for a unique cytoskeletal linkage.
In a remarkable study in this issue of Neuron, Brophy date for linking extracellular matrix receptors to the cy-
toskeleton during myelin formation. The importance ofand colleagues (Sherman et al., 2001), provide a novel
protein complex as a candidate. Schwann cells, like periaxin is underscored by the observation that periaxin
null mice develop a demyelinating neuropathy with atyp-epithelia, contain a bevy of molecules at the basal sur-
face that link the basal lamina to the cytoskeleton. For ical sensory disturbances (Gillespie et al., 2000). Based
on the chromosomal location of the human periaxin geneexample, laminin is important for normal myelination
(Bunge, 1992), and the laminin receptors 64 and 61 and the description of periaxin-deficient mice, several
recessive mutations of periaxin have been identified inintegrins are abundantly present (Feltri et al., 1994,
among several). However, unlike epithelia, Schwann hereditary demyelinating neuropathies (see, for exam-
ple, Boerkoel et al., 2001).cells do not organize hemidesmosomes, typically asso-
ciated with 64 integrin, in keeping with a distinct cy- In the current paper, Sherman et al. (2001) identify
and characterize periaxin-DRP2 interaction using yeasttoskeletal linkage in Schwann cells. In addition, Schwann
cells express another laminin receptor, dystroglycan. In two-hybrid or GST pulldown assays, and immunoprecip-
itation. DRP2 is closely related to the carboxyl portionthis study, Brophy and colleagues tie dystroglycan to a
Schwann cell-specific molecule, periaxin, via a bridge of dystrophin; it contains two spectrin-like repeats that
constitute the rod-like domain, followed by WW, EF-with the dystrophin-related protein 2 (DRP2) (see figure).
The dystrophin family includes several shorter iso- hands, ZZ, and coiled-coil carboxy terminal domains,
all common among dystrophins. Instead, the 75 residuesforms of dystrophin, resulting from the use of tissue-
specific promoters and alternative splicing, and two at the amino terminus of DRP2 are unique. Full interac-
tion with periaxin requires the conserved spectrin-likeclosely related proteins, utrophin and DRP2, encoded
by separate genes (Roberts, 2001). DRP2, like myelin, and WW domains of DRP2, although no interaction be-
tween periaxin and other dystrophin family membersis a vertebrate adaptation and is found at synapses in
the brain and in this study, highly enriched in Schwann was detected in two-hybrid assays. DRP2 and peri-
axin colocalize at the basal surface of myelin-formingcells. Schwann cells were already known to synthesize
and organize a dystrophin/dystroglycan complex. In ad- Schwann cells. In fact, further yeast two-hybrid experi-
ments suggest the basis of localization, as they providedition to DRP2, Schwann cells produce the short dys-
trophin isoform, Dp116, and utrophin. Using immuno- the first demonstration that DRP2 interacts with dystro-
glycan, presumably anchoring the periaxin/DRP2 com-precipitation, Imamura and colleagues (2000) had
characterized a putative dystroglycan complex that plex to the Schwann cell basal plasma membrane. In
parallel, the authors show that periaxin homodimerizescould link laminin to actin via Dp116 and utrophin. The
absence of an analogous skeletal muscle dystroglycan/ through its PDZ domain. The full periaxin/DRP2/dys-
troglycan complex was successfully affinity purifieddystrophin complex in Duchenne muscular dystrophy
produces membrane instability and muscle fiber degen- from nerve lysates with a periaxin antibody.
The authors then exploit this interaction to exploreeration with failed regeneration. However, genetic alter-
ations of dystrophin (including those that affect Dp116) the pathogenesis of periaxin mutations associated with
hereditary demyelinating neuropathies. In periaxin nulland utrophin in human or mouse probably do not cause
evident peripheral nerve disease (see, for example, Ra- mice, which manifest a mixture of hypermyelination and
demyelination, DRP2 but not other dystrophin familyfael et al., 1998). Could there be another dystroglycan
complex in Schwann cells? members, is mislocalized and partially depleted. The
authors postulate that periaxin homodimerizes andThe identification of periaxin in 1994 provided the first
clue. Periaxin is a PDZ domain-containing protein that serves as a scaffold upon which to assemble the DRP2/
dystroglycan complex. One caveat is that the affinity-was isolated in a screen based on detergent insolubility
for cytoskeleton-related proteins in peripheral nerve purified periaxin/DRP2/dystroglycan complexes also
contain Dp116 and utrophin, as well as actin. Thus, other(Gillespie et al., 1994). Periaxin is exquisitely Schwann
cell-specific, and its subcellular localization changes interactions and related functions of a larger assembly
containing periaxin may yet be revealed. This does not,during differentiation: embryonic Schwann cells localize
it to the nucleus, perinatal Schwann cells to the periaxo- however, diminish the specificity of the core periaxin/
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DRP2/dystroglycan complex. Periaxin and DRP2 are myelin. Or as firemen instruct schoolchildren, Schwann
cells may stop, DR(o)P2, and roll.specifically present or highly enriched in myelin-forming
Schwann cells, respectively, and DRP2 has thus far been
shown to interact with dystroglycan only in Schwann Lawrence Wrabetz and Maria Laura Feltri
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Feltri, M.L., Scherer, S.S., Nemni, R., Kamholz, J., Vogelbacker, H.,can complex is thought to buffer mechanical stress—or
Scott, M.O., Canal, N., Quaranta, V., and Wrabetz, L. (1994). Develop-through signaling. The authors speculate that a periaxin/
ment 120, 1287–1301.DRP2/dystroglycan complex could transduce signals
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What about a more general role in myelination? Cer- Sherman, D.L., Fabrizi, C., Gillespie, C.S., and Brophy, P.J. (2001).
tainly the phenotype of dystrophic (dy/dy) mouse sug- Neuron 30, this issue, 677–687.
gests that laminin mutations have their effect prior to
and during myelinogenesis (Bunge, 1992), suggesting as
one possible mediator the periaxin/DRP2/dystroglycan Knock Out of Directionassembly. It could simply subserve the demanding ar-
Selectivity in the Retinachitectural problem of myelinogenesis by linking laminin
in the basal lamina to the cytoskeleton. Or it could play
a role in signaling; laminin and basal lamina assembly
Retinal ganglion cells show direction selectivity in theirare thought to regulate myelin gene expression, for ex-
responses to moving stimuli. The circuitry necessaryample (see references in Sherman et al., 2001). An impor-
to generate directional selectivity in these cells hastant question is when interaction begins in developing
been long debated. Yoshida et al. (2001) use immuno-nerve. Periaxin is present before birth, DRP2 at least
toxin-mediated cell ablation to demonstrate that theby 10 days after birth (this study), and dystroglycan
starburst amacrine cell is at the core of this compu-perinatally. One interesting observation from this study
tation.is that the basic domain of periaxin is required for DRP2
binding. This same domain acts as a nuclear localization
signal in embryonic Schwann cells. Then periaxin relo- Visual motion detection is a classical problem of compu-
cates to the cytoplasm of Schwann cells perinatally just tational neuroscience. Despite many efforts during the
prior to myelination—does DRP2 appear at this time last 40 years, we still do not understand the synaptic
and mask the nuclear localization signal? In addition connectivity and signaling that result in direction selec-
to expression analysis, ongoing studies to disrupt the tivity (DS) in retinal ganglion cells. According to the
genes encoding DRP2 and dystroglycan either singly or model proposed by Barlow and Levick (1965), each gan-
doubly in the presence or absence of periaxin will better glion cell receives signals derived from two neighboring
define a role in myelin formation and maintenance. A image locations, one excitatory and one inhibitory (see
tantalizing hypothesis is that this complex appears and figure, panel A). The inhibitory input is displaced toward
alters the cytoskeletal linkage at the time when Schwann the preferred direction of the ganglion cell and, in addi-
tion, is delayed. Thus, a stimulus moving in the nullcells have exited from the cell cycle, and begin to form
